Clinical Trials on Asymptomatic Hyperuricemia in Denmark

Total 15 results

Nycomed

Completed

Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM)

Symptomatic Diabetic Peripheral Polyneuropathy

Denmark
Odense University Hospital

Recruiting

Early Initiated Vasopressor Therapy in the Emergency Department (VASOSHOCK)

Shock | Shock, Septic | Hypotension | Hypovolemia | Hypotension and Shock | Hypovolemic Shock | Hypotension Symptomatic | Hypovolemic

Denmark
Bone Therapeutics S.A
Nordic Bioscience A/S

Completed

Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis (JTA-KOA2)

Symptomatic Osteoarthritis of the Knee

Denmark, Belgium, United Kingdom, Czechia, Hong Kong, Moldova, Republic of, Poland
Abbott Medical Devices

Completed

FlexNav EU CE Mark Study

Symptomatic Severe Aortic Stenosis

Denmark, Switzerland, United Kingdom, Italy
Abbott Medical Devices

Completed

Portico TAVI Implant With Transfemoral Delivery System

Symptomatic Aortic Stenosis

United Kingdom, Germany, Netherlands, Denmark, Australia
Abbott Medical Devices

Recruiting

Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation (VANTAGE)

Symptomatic Severe Aortic Stenosis

Spain, Denmark, United Kingdom, France, Italy, Australia, Germany, Netherlands, Switzerland, Austria
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia (EARLY)

Asymptomatic Amyloid-positive

United States, Canada, United Kingdom, Belgium, Germany, Spain, Japan, Australia, Netherlands, Denmark, Mexico, Finland, Sweden
Abbott Medical Devices

Active, not recruiting

Portico NG Approval Study

Symptomatic Severe Aortic Stenosis

United States, Australia, Denmark, Italy, United Kingdom
Medtronic Cardiovascular

Active, not recruiting

SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial (SMART)

Aortic Valve Stenosis | Aortic Valve Replacement | Symptomatic Aortic Stenosis

United Kingdom, United States, Netherlands, Canada, Israel, Spain, Finland, Denmark, France, Germany, Switzerland, Italy, Portugal
Cytokinetics

Enrolling by invitation

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)

Symptomatic Hypertrophic Cardiomyopathy (HCM)

United States, France, Israel, Spain, United Kingdom, Italy, Portugal, Poland, Hungary, Denmark, Netherlands, Germany, Czechia
Theravance Biopharma

Terminated

Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (OAK)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Portugal, United Kingdom, France, Denmark, Ukraine, Israel, Estonia, Poland, Italy, Russian Federation, Australia, Austria, Bulgaria, Canada, Germany, New Zealand
Medtronic Cardiac Rhythm and Heart Failure
Medtronic Bakken Research Center

Completed

Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke (CRYSTAL-AF)

Cryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic Stroke

Netherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
Theravance Biopharma

Completed

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (SEQUOIA)

Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, Israel, Hungary, Portugal, Australia, Canada, Germany, Russian Federation, Estonia, France, Italy, United Kingdom, Denmark, Poland, New Zealand, Austria, Bulgaria, Ukraine
Theravance Biopharma

Recruiting

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy (CYPRESS)

MSA - Multiple System Atrophy | Symptomatic Neurogenic Orthostatic Hypotension

United States, Spain, United Kingdom, Hungary, Italy, Argentina, Austria, Poland, Germany, Portugal, Belgium, Brazil, Denmark, Canada, France, Chile, Estonia
Theravance Biopharma

Terminated

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (REDWOOD)

Parkinson's Disease (PD) | MSA | Symptomatic Neurogenic Orthostatic Hypotension | Pure Autonomic Failure (PAF)

United States, Spain, United Kingdom, Canada, France, Estonia, Australia, Israel, Denmark, Italy, Poland, New Zealand, Germany, Ukraine, Austria, Bulgaria, Portugal, Hungary, Russian Federation

Clinical Trials on Asymptomatic Hyperuricemia in Denmark

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations